MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
27.04
-0.62
-2.24%
After Hours: 27.04 0 0.00% 16:20 04/12 EDT
OPEN
27.52
PREV CLOSE
27.66
HIGH
27.57
LOW
26.66
VOLUME
637.96K
TURNOVER
0
52 WEEK HIGH
33.34
52 WEEK LOW
13.72
MARKET CAP
1.58B
P/E (TTM)
-19.4407
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PTGX last week (0401-0405)?
Weekly Report · 4d ago
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
NASDAQ · 04/05 16:00
Weekly Report: what happened at PTGX last week (0325-0329)?
Weekly Report · 04/01 11:20
Protagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnerships
TipRanks · 03/27 10:05
Weekly Report: what happened at PTGX last week (0318-0322)?
Weekly Report · 03/25 11:23
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Digital World Acquisition (DWAC) ahead of the potential listing of Trump Media & Technology. The Nevada Gaming Control Board report for February will be released. United Parcel Service (UPS) will hold its Analyst Day.
Seeking Alpha · 03/22 19:00
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
NASDAQ · 03/18 13:55
Weekly Report: what happened at PTGX last week (0311-0315)?
Weekly Report · 03/18 11:21
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.